益气复肝颗粒联合恩替卡韦治疗慢性乙型肝炎的临床研究  

Effect of Yiqi Fugan Granules(益气复肝颗粒)Combined with Entecavir on Chronic Hepatitis B

作　　者：张翠翠 李红[1] 王芳 苏萍 ZHANG Cuicui;LI Hong;WANG Fang;SU Ping(Tangshan Traditional Chinese Medicine Hospital,Tangshan 063000,Hebei,China)

机构地区：[1]唐山市中医医院,河北唐山063000

出　　处：《辽宁中医杂志》2025年第2期77-80,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：河北省中医药管理局科研计划项目(2022545)。

摘　　要：目的探讨益气复肝颗粒联合恩替卡韦治疗慢性乙型肝炎的临床效果。方法选取2020年10月-2021年10月该院收治的慢性乙型肝炎患者106例。采用随机数字表法分为A组30例、B组46例、C组30例。3组患者均给予骨化三醇胶丸、维生素C、复方维生素B、肌苷片等基础治疗,在此基础上,A组患者给予益气复肝颗粒治疗,B组患者给予益气复肝颗粒联合恩替卡韦胶囊治疗,C组患者给予恩替卡韦胶囊治疗。比较3组患者血清HBV-DNA、乙型肝炎表面抗原(hepatitis B surface antigen,HBsAg)、白细胞介素-2(interleukin-2,IL-2)水平、免疫功能水平。结果B组HBV-DNA载量明显降低,且低于A组和C组;B组CD_(3)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)比值分别为(65.85±9.63)%、(25.32±3.19)%、(1.13±0.65)%,与A组(57.54±8.71)%、(24.36±5.32)%、(1.88±0.68)%与C组(55.72±6.28)%、(28.72±4.06)%、(0.81±0.14)%比较(P<0.05);B组NK细胞、IL-2水平为(27.40±3.96)%、(3.67±1.05)与A组、B组比较(P<0.05),A组治疗前后CD_(4)^(+)百分比增加与HBV-DNA载量减少呈显著性正相关(P<0.05);B组治疗前后CD_(3)^(+)增加、NK细胞增加、CD_(8)^(+)百分比减少与HBV-DNA载量减少呈显著正相关(P<0.05);治疗后,HBV-DNA转阴率B组为82.61%高于A组的50.00%、C组的6.67%,HBsAg转阴率B组为84.78%高于A组的63.67%、C组的3.33%(P<0.05)。结论益气复肝颗粒联合恩替卡韦治疗CHB临床效果显著,可提升患者的免疫功能和肝功能。Objective To explore the clinical study of Yiqi Fugan Granules(益气复肝颗粒)combined with entecavir in the treatment of chronic hepatitis B.Methods A total of 106 patients with chronic hepatitis B who were admitted to the hospital from October 2020 to October 2021 were selected.The patients were divided into group A(30 cases),group B(46 cases)and group C(30 cased)by random number table method.The patients of thethree groupswere all given calcitriol capsules,vitamin C,compound vitamin B,inosine tablets and other basic treatments.The patients in group A were given Yiqi Fugan Granules for treatment,those in group B were given Yiqi Fugan Granules combined with entecavir capsules,and those in group C were treated with Entecavir Capsules.The levels of serum hepatitisBvirus(HBV)-DNA,hepatitis B surface antigen(HBsAg),interleukin-2(IL-2)and immune function were compared among the three groups.Results The HBV-DNA load in group B was significantly lower than that in group A and C.The ratios of CD_(3)^(+),CD_(8)^(+)and CD_(4)^(+)/CD_(8)^(+)in group B were(65.85±9.63)%,(25.32±3.19)%and(1.13±0.65)%,respectively,and had significant difference compared with those of group A[(57.54±8.71)%,(24.36±5.32)%,(1.88±0.68)%]and group C[(55.72±6.28)%,(28.72±4.06)%,(0.81±0.14)%](P<0.05).The levels of natural killercells(NK)[(27.40±3.96)%]and IL-2[(3.67±1.05)ng/mL]in group B weresignificantcompared with those of group A and group B(P<0.05).The increase in CD_(4)^(+)percentage before and after treatment in group A was significantly correlated with the decrease in HBV-DNA load.There was significant positive correlation(P<0.05).The increase of CD_(3)^(+)and NK cells and the decrease of CD_(8)^(+)percentage were positively correlated with HBV-DNA load in group B before and after treatment(P<0.05).After treatment,the negative rate of HBV-DNA in group B was 82.61%,which was higher than that in group A(50.00%)and group C(6.67%)(P<0.05).Conclusion The clinical effect of Yiqi Fugan Granules combined with entecavir in the treatment o

关 键 词：慢性乙型肝炎 益气复肝颗粒 恩替卡韦 免疫功能 

分 类 号：R256.4[医药卫生—中医内科学]